Impact Factor 4.416

Frontiers journals are at the top of citation and impact metrics

Systematic Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2018.00363

Vestibulotoxicity associated with platinum-based chemotherapy in survivors of cancer: a scoping review

  • 1University of Nottingham, United Kingdom
  • 2NIHR Nottingham Hearing Biomedical Research Unit, United Kingdom
  • 3Nottingham University Hospitals NHS Trust, United Kingdom

Background: Cochleotoxicity following the treatment with platinum-based chemotherapy is well documented. The potential for vestibulotoxicity is still unclear. This scoping review examined the extent of current research literature, summarized research findings and identified research gaps regarding vestibular-related adverse effects associated with platinum-based chemotherapy in survivors of cancer.

Methods: Inclusion criteria followed the PICO principles: Participants, adult and paediatric cancer patients of any cancer type; Intervention, platinum-based chemotherapy (such as cisplatin, carboplatin, and oxaliplatin); Control, none or any; Outcomes, vestibular-related adverse effects. English language articles published since 1978 were retrieved. Seventy-five eligible studies were identified from a systematic literature search, and relevant data were charted, collated, and summarized.

Results: Testing for vestibulotoxicity predominately featured functional evaluation of the horizontal semicircular canal using the caloric and rotational tests. The rate of abnormal vestibular function test results after chemotherapy administration varied from 0-50%. The results of objective testing did not always correspond to patient symptoms. There is tentative support for patients with pre-existing loss of vestibular function to be more likely to experience vestibular toxicity after dosing with cisplatin.

Conclusions: A number of studies reported significant evidence of vestibular toxicities associated with platinum-based chemotherapy, especially cisplatin. This scoping review emphasizes that vestibular toxicity needs more attention and comprehensive evaluation. Specifically, studies that analyse cumulative dose of platinum-based chemotherapy, affected sites of lesion in vestibular end organs, and the correlation and temporal patterns of cochlear and vestibular toxicity are needed.

Keywords: Vestibulotoxicity, vestibular, adverse effect, Platinum-based chemotherapy, Cancer

Received: 04 Jul 2018; Accepted: 16 Aug 2018.

Edited by:

Marc Poirot, Institut National de la Santé et de la Recherche Médicale (INSERM), France

Reviewed by:

Lisa Cunningham, National Institutes of Health (NIH), United States
Etienne Chatelut, Institut universitaire du Cancer de Toulouse Oncopole, France  

Copyright: © 2018 Prayuenyong, Taylor, Pearson, Gomez, Patel, Hall, Kasbekar and Baguley. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Pattarawadee Prayuenyong, University of Nottingham, Nottingham, United Kingdom, msxpp4@nottingham.ac.uk